Search

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more

Presidential Speakers

Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.  

Friday, June 13, 2025 - Presidential Session I

Immunotherapy (TCR related)

Prof.

Read more

EHA Statement of Solidarity with Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Read more